The FDA just held a public meeting to discuss the results from two major heart safety trials conducted on the DPP-4 inhibitor drugs Onglyza and Nesina. Both trials suggested that the drugs do not increase the risk of cardiovascular events, such as heart attacks and strokes. Following a long day of testimonies, the FDA committee voted that both Onglyza and Nesina passed the heart safety requirements necessary to stay on the market.